Changes in the factors associated with the renal prognosis during 12 months before and after administration of luseogliflozin in patients with type 2 diabetes

Changes in the factors associated with the renal prognosis during 12 months before and after administration of luseogliflozin in patients with type 2 diabetes - Changes in the factors associated with the renal prognosis during 12 months before and after administration of luseogliflozin in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041193

Enrollment

200

Registered

2020-07-22

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were administered luseogliflozin

Exclusion criteria

Exclusion criteria: Subjects with replacement from other SGLT2 inhibitors or GLP-1 receptor antagonists, those with observation period less than 12 months, those with change of diuretics or anti-hypertensive agents during the observation period and those with add-on of GLP-1 receptor antagonists during the observation period

Design outcomes

Primary

Measure	Time frame
Changes in eGFR during 12 months before and after administration of luseogliflozin	—

Secondary

Measure	Time frame
Changes in urinary protein excretion, urinary albumin excretion and urinary L-FABP during 12 months after administration of luseogliflozin	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results